Chikungunya Pipeline Report: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Key Companies - Valneva SE (VLA1553), Moderna, Themis, FIT Biotech, Emergex, Auro Vaccines, Riboscience

As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Chikungunya therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Chikungunya Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chikungunya Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Chikungunya Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Chikungunya Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chikungunya treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chikungunya market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

DelveInsight's report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chikungunya Therapeutics Analysis
There are approx. 10+ key companies which are developing therapies for Chikungunya virus infections. Currently, Valneva has its Chikungunya virus infection drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Chikungunya Therapeutics Market include:
• Valneva
• Moderna Therapeutics
• Themis Bioscience
• FIT Biotech
• Bharat Biotech
• Emergex Vaccines
• Emergent BioSolutions
• Indian Immunologicals Ltd.
• Auro Vaccines
• Riboscience
And many others

Chikungunya Virus Infections Drugs Covered in the report include:
• VLA1553: Valneva
Valneva is developing VLA1553, a chikungunya vaccine candidate in Phase III clinical trials that targets long-term protection following the administration of a single dose. Valneva reported positive topline results from a Phase 3 pivotal trial in August 2021. VLA1553 has received Fast Track and Breakthrough Therapy designation from the FDA and PRIME designation from the EMA.

Other Emerging Therapies are Covered in Detailed in Report. Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Chikungunya Current Treatment Patterns
4. Chikungunya - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chikungunya Late Stage Products (Phase-III)
7. Chikungunya Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chikungunya Discontinued Products
13. Chikungunya Product Profiles
14. Chikungunya Key Companies
15. Chikungunya Key Products
16. Dormant and Discontinued Products
17. Chikungunya Unmet Needs
18. Chikungunya Future Perspectives
19. Chikungunya Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.